[
    {
        "file_name": "FIBROGENINC_10_01_2014-EX-10.11-COLLABORATIONAGREEMENT.txt",
        "perturbation": [
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "1.46 \"Lead Compound\" shall mean any compound Controlled by FG that is designated by FG as a lead compound for clinical development in an Indication in accordance with Section 4.3 for the duration of such designation. Any Lead Compound which receives a Marketing Approval in the Astellas Territory shall remain a Lead Compound for the duration of such Marketing Approval. As of the Effective Date, FG-2216 shall be deemed to be a Lead Compound.",
                "changed_text": "1.46 \"Lead Compound\" shall mean any compound Controlled by FG that is designated by FG as a lead compound for clinical development in an Indication in accordance with Section 4.3 for the duration of such designation. Any Lead Compound which receives a Marketing Approval in the Astellas Territory may or may not remain a Lead Compound, subject to FG's discretion. As of the Effective Date, FG-2216 may be deemed to be a Lead Compound.",
                "explanation": "The original text states that a Lead Compound receiving Marketing Approval 'shall' remain a Lead Compound, providing certainty. The modification replaces 'shall' with 'may or may not remain,' introducing uncertainty and FG's discretion, contradicting the original mandatory language. Furthermore, it changes 'shall be deemed' to 'may be deemed' removing certainty.",
                "location": "ARTICLE 1 DEFINITIONS"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "8.3.5 Activities in Astellas Territory by FG During the term of this Agreement, FG shall not Commercialize by itself or through its Sublicensee any Lead Compound or other compound, whether or not designated as a Lead Compound, within the Field in the Astellas Territory, or any Lead Compound outside the Field in the Astellas Territory, provided, however, that FG may develop a Lead Compound or other compound in the Astellas Territory in those Indications for which Astellas has determined not to pursue Commercialization or for which Astellas has lost the right to pursue Commercialization due to failure to meet diligence obligations hereunder; and provided, further, that FG may Commercialize compounds other than Lead Compounds outside the Field in the Astellas Territory, irrespective of whether such compound has the effect of stabilizing HIF causing the stimulation of erythropoiesis (including an increase in endogenous erythropoietin production) and/or a subsequent increase in hematocrit through modulation of prolyl hydroxylase and/or asparaginyl hydroxylase.",
                "changed_text": "8.3.5 Activities in Astellas Territory by FG During the term of this Agreement, FG shall not Commercialize by itself or through its Sublicensee any Lead Compound or other compound, whether or not designated as a Lead Compound, within the Field in the Astellas Territory, or any Lead Compound outside the Field in the Astellas Territory. FG may develop a Lead Compound or other compound in the Astellas Territory regardless of Astellas's commercialization plans. FG may also Commercialize compounds other than Lead Compounds outside the Field in the Astellas Territory, irrespective of whether such compound has the effect of stabilizing HIF causing the stimulation of erythropoiesis (including an increase in endogenous erythropoietin production) and/or a subsequent increase in hematocrit through modulation of prolyl hydroxylase and/or asparaginyl hydroxylase.",
                "explanation": "The original text contains specific conditions under which FG can develop/commercialize in Astellas Territory. The modified text removes those conditions, stating FG 'may' develop regardless of Astellas' plans. It removes the restriction, creating a contradiction.",
                "location": "ARTICLE 8 MARKETING RIGHTS"
            },
            {
                "type": "Structural Flaws - In Text Contradiction",
                "original_text": "12.1 Procedures. FG shall have the exclusive right to determine the methods and procedures for the manufacture of all Lead Compounds. If FG intends to make any change in the methods or procedures, including, without limitation, manufacturing process, analyzing process and/or site change for manufacture of the Lead Compounds, FG shall notify Astellas in writing of such intended change; provided, that if in Astellas' reasonable opinion, such change may lead to any amendment to the relevant Marketing Approval or Marketing Approval Application, Astellas shall use best efforts to (i) as soon as possible petition the Japanese Ministry of Health, Labor and Welfare to make the change without an amendment to the Marketing Approval or MAA and shall concurrently prepare an application for amendment to the Marketing Approval or MAA, and (ii) if the Japanese Ministry of Health, Labor and Welfare determines such an amendment is required, shall notify FG and submit the application for amendment immediately following notice of such requirement, and FG shall not make the intended change without a prior written consent from Astellas, such consent not to be unreasonably withheld or delayed, provided, further, that consent shall be deemed granted upon notice that an amendment is not required or approval of an amendment from the Japanese Ministry of Health, Labor and Welfare. FG shall provide Astellas with all the data and information necessary for Astellas to amend the Marketing Approval or MAA in Astellas Territory and shall continue to supply Astellas with the Lead Compound as manufactured with the manufacturing methods and procedures or at the manufacturing site described in Astellas' (or its Affiliate's or Sublicensee's) then current Marketing Approval or MAA until Astellas will have finished the necessary amendment to the relevant Marketing Approval or MAA or received notice that an amendment is not required.",
                "changed_text": "12.1 Procedures. FG shall have the exclusive right to determine the methods and procedures for the manufacture of all Lead Compounds. FG is not obligated to inform Astellas of any changes to its manufacturing processes. FG shall have full control over manufacturing of lead compounds.",
                "explanation": "The original text mandates FG to notify Astellas of manufacturing changes and seek consent under certain conditions. The modified text states that FG is NOT obligated to inform Astellas, directly contradicting the original notification requirement, creating uncertainty.",
                "location": "ARTICLE 12 MANUFACTURING RIGHTS"
            }
        ]
    }
]